Founded in 2001, Mycenax Biotech Inc. (MBI) is a CDMO company offering integrated services for the development and manufacturing of biologic products, including cell line generation, process, formulation, and analytical method developments, GMP production for both mammalian and microbial systems, and fill-finish for both liquid and lyophilized forms.
MBI has extensive experience in developing biologic products for our clients around the globe. Ranging from small peptides, fusion proteins, and monoclonal antibodies, to cell therapy products, we provide our clients with time- and cost-effective services through our high-standard technology platforms and PIC/S GMP certified manufacturing facility. For the cell line development, we recently introduced the Beacon® Optofluidic System (Berkeley Lights, US) to streamline the workflow and provide strong evidence for monoclonality. For process development, we are pioneered in developing continuous bioprocess. For GMP manufacturing, our 2 nd GMP facility, which hosts 2 production lines with up to six 2,000L bioreactors will be completed in mid-2021 to further expand our GMP production capacity.
With our innovative technology and qualified GMP facilities, we are the best partner for clients worldwide for developing biologic products at all developmental stages.
For more information, please visit our booth or website at:Â http://www.mycenax.com.tw/en